|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02348 DAWNRAYS PHARMA
Nominal 
1.250 +0.010 (+0.806%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Turnover | 577,447 | -11.151% | 649,920 | 623,478 | 608,589 | 488,993 |
| Cost of Sales | (239,535) | -16.849% | (288,071) | (231,200) | (235,498) | (224,257) |
| Gross Profit | 337,912 | -6.615% | 361,849 | 392,278 | 373,091 | 264,736 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (3,696) | -81.791% | (20,298) | (20,493) | (17,122) | (9,960) | |
| Profit / (Loss) before Taxation | 556,752 | 70.151% | 327,211 | 225,591 | 211,082 | 161,905 | |
| Taxation | (65,169) | -10.778% | (73,041) | (53,765) | (45,391) | (34,353) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 1,463 | -17.391% | 1,771 | (165) | 955 | 2,139 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 493,046 | 92.640% | 255,941 | 171,661 | 166,646 | 129,691 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Net Finance Costs / (Income) | (12,838) | 26.946% | (10,113) | (8,792) | (9,446) | (3,802) |
| Depreciation & Amortisation | 41,868 | 13.187% | 36,990 | 24,025 | 25,431 | 26,726 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| EPS (cts) | 32.860 | 92.501% | 17.070 | 11.456 | 11.127 | 8.362 |
| DPS (cts) | 1.369 | -- | 1.374 | 1.319 | 1.249 | 1.339 |
| Dividend Payout Ratio (%) | 4.166% | -- | 8.049% | 11.510% | 11.227% | 16.013% |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 2.178 | -- | 1.872 | 1.650 | 1.474 | 1.348 |
| Remarks: | Real time quote last updated: 13/11/2024 14:32 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 493,046,000 |
| %Change | 92.640% |
| EPS / (LPS) | RMB 0.329 |
| NBV Per Share (¥) | RMB 2.178 |